Comparative in Vitro Cellular Data Alone Is Insufficient to Predict Clinical Responses and Guide Choice of BCR-ABL Inhibitor to Treat Imatinib-Resistant Chronic Myeloid Leukemia

被引：0
|
作者：
Laneuville, Pierre [1 ]
DiLea, Clifford [2 ]
Mestan, Juergen [3 ]
Yin, Ophelia [2 ]
Woodman, Richard C. [2 ]
Manley, Paul [3 ]
机构：
[1] McGill Univ, Ctr Hlth, Montreal, PQ, Canada
[2] Novartis Pharmaceut, E Hanover, NJ USA
[3] Novartis Pharma AG, Basel, Switzerland
来源：
BLOOD | 2009年 / 114卷 / 22期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：211 / 211
页数：1
相关论文
共 50 条
  • [1] COMPARATIVE IN VITRO CELLULAR DATA ALONE IS INSUFFICIENT TO GUIDE CHOICE OF BCR-ABL INHIBITOR TO TREAT IMATINIB-RESISTANT CHRONIC MYELOID LEUKEMIA
    Laneuville, P.
    DiLea, C.
    Mestan, J.
    Yin, O.
    Manley, P. W.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 260 - 261
  • [2] Comparative In Vitro Cellular Data Alone Are Insufficient to Predict Clinical Responses and Guide the Choice of BCR-ABL Inhibitor for Treating Imatinib-Resistant Chronic Myeloid Leukemia
    Laneuville, Pierre
    DiLea, Clifford
    Yin, Ophelia Q. P.
    Woodman, Richard C.
    Mestan, Juergen
    Manley, Paul W.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (11) : E169 - E171
  • [3] Comparative In Vitro Cellular Data Alone Are Insufficient to Predict Clinical Responses and Guide the Choice of BCR-ABL Inhibitor for Treating Imatinib-Resistant Chronic Myeloid Leukemia Reply
    Gambacorti-Passerini, Carlo
    Piazza, Rocco
    Perini, Pietro
    Rostagno, Roberta
    Redaelli, Sara
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (11) : E172 - E172
  • [4] Targeting the imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia through a novel BCR-ABL inhibitor
    Gupta, Pranav
    Kathawala, Rishil
    Wei, Liuya
    Wang, Fang
    Wang, XiaoKun
    Druker, Brian J.
    Fu, Li-Wu
    Chen, Zhe-Sheng
    CANCER RESEARCH, 2017, 77
  • [5] Spectrum of BCR-ABL mutations in Azerbaijanian imatinib-resistant patients with chronic myeloid leukemia
    Hasanova, Aypara
    Asadov, Chingiz
    Karimova, Nigar
    Shirinova, Aytan
    Aliyeva, Gunay
    Alimirzoyeva, Zohra
    PATHOLOGY & ONCOLOGY RESEARCH, 2023, 29
  • [6] ASSESSMENT OF THE RESULT OF BCR-ABL MUTATION ANALYSIS IN IMATINIB-RESISTANT CHRONIC MYELOID LEUKEMIA PATIENTS
    Demircioglu, S.
    Balasar, M.
    Yildirim, M.
    LEUKEMIA RESEARCH, 2016, 49 : S40 - S40
  • [7] Molecular screening and the clinical impacts of BCR-ABL KD mutations in patients with imatinib-resistant chronic myeloid leukemia
    Kockan, Betul
    Toptas, Tayfur
    Atagunduz, Isik
    Tuglular, Ayse Tulin
    Ozer, Ayse
    Akkiprik, Mustafa
    ONCOLOGY LETTERS, 2018, 15 (02) : 2419 - 2424
  • [8] AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia
    Golemovic, M
    Verstovsek, S
    Giles, F
    Cortes, J
    Manshouri, T
    Manley, PW
    Mestan, J
    Dugan, M
    Alland, L
    Griffin, JD
    Arlinghaus, RB
    Sun, T
    Kantarjian, H
    Beran, M
    CLINICAL CANCER RESEARCH, 2005, 11 (13) : 4941 - 4947
  • [9] AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has significant activity in imatinib-resistant Bcr-Abl positive chronic myeloid leukemia (CML)
    Giles, FG
    Ottmann, OT
    Cortes, J
    Wassmann, B
    Bhalla, K
    Jones, D
    Hochhaus, A
    Rae, PE
    Tanaka, C
    Alland, L
    Dugan, M
    Albitar, M
    Kantarjian, H
    BRITISH JOURNAL OF HAEMATOLOGY, 2005, 129 : 3 - 3
  • [10] AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has significant activity in imatinib-resistant Bcr-Abl positive chronic myeloid leukemia (CML).
    Kantarjian, H
    Ottmann, O
    Cortes, J
    Wassmann, B
    Jones, D
    Hochhaus, A
    Alland, L
    Dugan, M
    Albitar, M
    Giles, F
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 195S - 195S
12345